Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique

International Journal of STD and AIDS

Volumn 23, Issue 6, 2012, Pages 403-407

  Chu, K M ^a   ManZi, M ^b   Zuniga, I ^a   Biot, M ^a   Ford, N P ^a   Rasschaert, F ^b   Zachariah, R ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

Author keywords

Africa; Aids; Antiretroviral therapy; Efavirenz; Hepatotoxicity; HIV; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; EFAVIRENZ; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOZAMBIQUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; BENZOXAZINES; CLINICAL PROTOCOLS; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; KENYA; MALE; MOZAMBIQUE; NEVIRAPINE; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84864035780     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009328     Document Type: Article

References (26)

1. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. See: www.who.int/3by5/publications/en/arv_eng.pdf (last checked 25 June 2012)
2. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;44:456-462
3. Pharmaceuticals BI. Viramune Package Insert2005, Ridgefield, CT
4. Viramune Package Insert. 2008. See http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf (last checked 14 July 2008)
5. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268
6. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-829
7. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl. 1): S21-33
8. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006;17:364-369, 370
9. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263
10. Wooltorton E. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ 2004;170:1091
11. AIDS Clinical Trials Group Division of AIDS for grading the severity of adult and pediatric adverse advents. 2004. See http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf. (last checked 24 July 2008)
12. Bartlett J, Gallant J. Medical Management of HIV Infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group, 2007
13. Carr A. Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 2002;360:81-85
14. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44:371-376
15. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003;17:2191-2199
16. Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR. Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:83-86
17. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006;43:501-503
18. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006;20:1163-1169
19. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007;370:12-14
20. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. AIDS 2006;20:2233-2236
21. Torti C, Costarelli S, De Silvestri A, et al. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4{thorn} T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Saf 2007;30:1161-1169
22. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21:1301-1308
23. Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 2010;5:e9183
24. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010;14:e1024-1031
25. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-1485
26. Parboosing R, Paruk I, Lalloo UG. Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naive patients is associated with renal insufficiency and increased mortality. J Med Virol 2008;80:1530-1536